Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.
About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of ...
A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...
Verastem Oncology Inc. and Genfleet Therapeutics Ltd. have inked a discovery and development deal to advance three oncology discovery programs targeting RAS pathway-driven cancers. The collaboration ...
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategyERAS-0015’s promising early clinical data ...
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
Using primary samples from the InterMEL study, a retrospective cohort of cases with specimens collected from an international consortium with participating institutions throughout the United States ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results